New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

Gout flares are commonly underreported among U.S. adults with gout, according to a study published in the January issue ...

The refractory gout market is growing because of the rising prevalence of gout brought on by aging populations and changes in ...

In a significant milestone for Ayurvedic medicine, Amrith Noni has successfully completed human clinical trials for its ...

Gout is a common type of inflammatory arthritis that occurs due to uric acid crystallisation and subsequent build-up in the ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...

Researchers have found that reduced pulmonary function strongly increases the risk of developing gout. Pulmonary function is ...

In the Year of the Blue Snake, 2025, there is growing anticipation about how domestic new drugs will perform in the global ...

Some other medicines that are slated to become blockbusters in the near future include GSK’s vaccine candidate GSK-3536819 ...

Colchicine prophylaxis during initiation of urate-lowering therapy in patients with gout was associated with a reduced risk ...